ABSTRACT
Tumor-induced osteomalacia (TIO) is a chronic condition associated with muscle weakness and long-term disability. We conducted a cross-sectional study of patients diagnosed with TIO who had been referred to our institution between May 2018 and December 2019. Our aim was to assess health-related quality of life (HRQoL), fatigue, pain, and muscle mass and strength in these patients. Detailed information was obtained regarding general characteristics, initial symptoms and biochemical parameters measured at diagnosis and on the first visit to our institution. Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale, pain using the Brief Pain Inventory–Short Form (BPI-sf) scale and HRQoL by the 36-item Short Form survey (SF-36) questionnaire. Eight patients were included in the study: three without tumor localization, four with nonremission after surgery, and one with clinical recurrence 2 years after surgery. Fatigue experienced by patients with TIO was significantly higher compared to the general population (p < .0001). The physical summary measure of the SF-36 showed significantly lower values than those of the Argentinean population with chronic conditions (mean 20.4 versus 45.9, p < .0001). According to the BPI-sf, patients with TIO have moderate average pain and the pain interferes severely with walking, general activities, work, and mood. Seven patients had a diagnosis of sarcopenia, four of which had severe sarcopenia. To our best knowledge, this is the first study aimed to quantify fatigue, pain, HRQoL, and muscle mass and strength in a group of patients with TIO. We hope our results contribute to a better understanding of the burden of disease and to establish a basis for future studies—with larger samples—which will make it possible to assess the efficacy of therapeutic interventions for these conditions. © 2020 American Society for Bone and Mineral Research © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

KEY WORDS: TUMOR-INDUCED OSTEOMALACIA; HEALTH-RELATED QUALITY OF LIFE; MUSCLE STRENGTH; BONE PAIN; FATIGUE

Introduction
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome, caused by overproduction of fibroblast growth factor 23 (FGF23)—or other phosphatonin—secreted by a mesenchymal tumor. The largest cohort from a single center included 230 patients. FGF23 excess leads to hypophosphatemia due to renal phosphate wasting and inappropriately normal or low 1.25 dihydroxyvitamin D. As a result, patients often present with a long history of musculoskeletal pain, fatigue, proximal muscle weakness, gait disturbance, and multiple fractures. These debilitating symptoms are a consequence of severe hypophosphatemia and can lead to long-term disability and considerable morbidity.
Although complete tumor resection results in resolution of symptoms in most patients, the diagnosis of TIO is commonly delayed because of its rarity and unspecific symptoms, and because tumor localization remains a challenging task.

In clinical practice TIO is largely known as a chronic condition that causes muscle quality deterioration and has a significant impact on quality of life (QoL). Nevertheless, limited research has been done to quantify the clinical burden of disease in this group of patients. The aim of our study was to evaluate health-related quality of life (HRQoL), fatigue, pain, and muscle mass and strength in a group of adult patients with TIO referred to our institution.

**Patients and Methods**

**Selection of patients**

We included adult patients with clinical diagnosis of TIO referred to our institution between May 2018 and December 2019. Diagnosis of TIO was based on the presence of a compatible clinical presentation and hypophosphatemia associated with a low tubular reabsorption of phosphate (TRP), in the absence of a relevant family history. For tumor localization, if it was clinically evident on physical examination, directed images were obtained (CT, MRI, or ultrasonography) to adequately characterize the lesion. Otherwise, functional imaging was performed.

The study was approved by Institutional Ethics Committee: Comité de Ética en Investigación del Instituto Nacional de Psicopatología (CEIINAPsi).

**Clinical characteristics**

Detailed information regarding general characteristics (age at diagnosis, gender, height, weight, time from onset to diagnosis, number of physicians seen from onset to diagnosis, time of follow-up, tumor localization) and initial symptoms (bone and muscle pain, fragility fractures, and mobility impairment) were obtained through a medical interview and clinical records sent by the referring physician.

Clinical status at the time of first visit to our institution was recorded as: (i) patients without tumor localization, (ii) patients with nonremission after tumor resection, (iii) patients with recurrence after tumor resection, and (iv) patients with full recovery after tumor resection.

**Biochemical features and bone mineral density**

Biochemical parameters measured at diagnosis and on the first visit to our institution (calcium, phosphate, creatinine, 25-hydroxyvitamin D, parathyroid hormone, alkaline phosphatase, and TRP) were assessed.

FGF23 levels were measured at our institution by the enzyme-linked immunosorbent assay using the human intact FGF-23 ELISA Kit (MyBioSource Inc., San Diego, CA, USA). We established a normal range of intact FGF23 for healthy persons between 7.5 and 76 pg/mL. According to Endo and colleagues, in adults, serum phosphate level lower than 2.5 mg/dL and FGF23 level higher than 30 pg/mL by the intact FGF23 assay indicate the presence of diseases caused by excess actions of FGF23.

Bone mineral density (BMD) (g/cm²) was measured by dual-energy X-ray absorptiometry (DXA) with GE Lunar Prodigy equipment (GE Lunar, Madison, WI, USA) at the lumbar spine (L1–L4), femoral neck, and total hip. A Z-score <2 was considered low BMD.

**Muscle mass, muscle strength, and physical performance**

Muscle mass was determined in the four limbs (appendicular skeletal muscle mass [ASMM]) by DXA. The ASM index was defined as ASM/height² (kg/m²). Sarcopenia was defined as <2 standard deviations (SDs) below the sex-specific mean of young adults (7 kg/m² for men and 5.5 kg/m² for women), according to the latest European consensus.

Muscle strength was evaluated by hand-grip strength assessment (Jamar Hydraulic Hand Dynamometer, Patterson Medical, Warrenville, IL, USA) in the dominant hand. The best result of three trials was recorded. According to the European Working...
Table 1. Clinical and Biochemical Characteristics of the Eight Patients With Tumor-Induced Osteomalacia

| Characteristic                                      | Value                  | Reference range |
|-----------------------------------------------------|------------------------|-----------------|
| **Demographic data**                                |                        |                 |
| Gender, female, n (%)                               | 5 (62)                 |                 |
| Age at diagnosis (years), median (range)            | 46 (27–56)             |                 |
| Age at first visit to our institution (years)       | 47 (28–65)             |                 |
| Time from onset to diagnosis (years), median (range)| 3.3 (2–10)             |                 |
| Time of follow-up (years), median (range)          | 1.6 (0.8–14)           |                 |
| Number of physicians seen from onset to diagnosis, median (range) | 7 (2–15) | |
| Height (m), mean ± SD                              | 1.52 ± 0.16            |                 |
| BMI (kg/m²), mean ± SD                             | 27.8 ± 7.8             |                 |
| **Initial symptoms**                                |                        |                 |
| Bone pain, n (%)                                    | 8 (100)                |                 |
| Fracture, n (%)                                     | 7 (87)                 |                 |
| Muscle pain, n (%)                                  | 7 (87)                 |                 |
| Progressive mobility impairment, n (%)              | 7 (87)                 |                 |
| **Biochemical features at diagnosis**               |                        |                 |
| Serum calcium (mg/dL), mean ± SD                   | 9.35 ± 0.24            | 8.5–10.5        |
| Serum phosphate (mg/dL), mean ± SD                 | 1.45 ± 0.22            | 2.5–4.5         |
| 25OHD (ng/mL), median (range)                       | 37.8 (8.4–70.6)        |                 |
| PTH (pg/mL), median (range)                         | 67.4 (43–168)          | 10–65           |
| Creatinine (mg/dL), mean ± SD                      | 1.00 ± 0.69            | 0.7–1.2         |
| TRP, mean ± SD                                      | 0.78 ± 0.07            | 0.85–1          |
| ALP (IU/L), median (range)                          | 294 (130–1171)         | 30–120          |
| **Biochemical features at first visit to our institution** |                        |                 |
| Serum calcium (mg/dL), mean ± SD                   | 9.72 ± 0.16            | 8.5–10.5        |
| Serum phosphate (mg/dL), mean ± SD                 | 2.08 ± 0.6             | 2.5–4.5         |
| 25OHD (ng/mL), median (range)                       | 30.7 (19.9–54.3)       |                 |
| PTH (pg/mL), median (range)                         | 31.8 (28.4–179.7)      | 10–65           |
| β-CTX (ng/mL), median (range)                       | 0.597 (0.135–1.255)    | 0.07–0.550*     |
| TRP, mean ± SD                                      | 0.72 ± 0.43            | 0.85–1          |
| Bone specific ALP (U/L), median (range)             | 61.7 (63.8–92.6)       | <21.3           |
| iFGF23 (pg/mL), median (range)                      | 82.5 (69–150)          | 47.5–76         |

25OHD = 25-hydroxyvitamin D; ALP = alkaline phosphatase; iFGF23 = intact fibroblast growth factor 23; PTH = parathyroid hormone; SD = standard deviation; TRP = tubular reabsorption of phosphate; β-CTX = C-terminal cross-linked telopeptide of type I collagen.

*Normal reference for premenopausal women: 0.074–0.550; for 30-year-old to 50-year-old men: 0.304–0.850.

Group on Sarcopenia in Older People 2 (EWGSOP2), low strength was defined as <16 kg in women and <27 kg in men.\(^{17}\)

Physical performance was assessed by the 4-m Walk Gait Speed and Sit to Stand Tests. The 4-m Walk Gait Speed Test was performed after a practice test and low walking speed was defined as walking slower than 0.8 m/s.\(^{17}\) Participants were instructed to stand with both feet touching the starting line and to begin walking at their usual pace. In the Sit to Stand Test, the time taken for five repetitions without using hands was recorded. Low sit-to-stand performance was defined as >15 s for five full stands, according to the EWGSOP2.\(^{17}\)

Statistical analysis

Quantitative data are presented as the mean ± SD or the median and range. Categorical data are presented as frequencies and percentages (%). To compare means, the Student’s t test was used for parametric variables and the Mann-Whitney U test for nonparametric variables. The normal distribution of continuous data was assessed using the Kolmogorov-Smirnov or the Shapiro-Wilkes test when appropriate. The Spearman’s rank correlation coefficient was used to evaluate the strength of relationship between age at diagnosis, time from onset to diagnosis, phosphate levels, FACIT-Fatigue score, SF-36 domains, BPI-score, and muscle health parameters. A p value <.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS software, v.20 (IBM Corp., Armonk, NY, USA).

Results

Patient characteristics

Eight adult patients with clinical diagnosis of TIO were referred to our institution. Tumor localization was not possible in three. These patients (40, 44, and 48 years old at diagnosis) did not have bone or dental disorders in childhood or a family history compatible with XLH. Tumors with histopathologic confirmation of mesenchymal origin, mixed connective tissue type, were found in feet (n = 2), pelvis (n = 1), vertebrae (n = 1), and head (n = 1). Four patients were in nonremission after surgery and one patient had had a recurrence 2 years after surgery.

The clinical and demographic characteristics of the patients in our cohort are detailed in Table 1. Median time from symptoms onset to correct diagnosis was 3.3 years.\(^{2–10}\) All of them had been initially misdiagnosed with at least five incorrect diagnosis including osteoporosis, hip osteonecrosis, complex regional pain syndrome, and lumbar pain. A median of seven physicians\(^{2–15}\) had evaluated these patients before reaching the diagnosis of
TIO and in all cases the correct diagnosis was finally made by an endocrinologist. All patients presented bone pain as an initial symptom. Muscle pain (87%) and progressive mobility impairment (87%) were also present at onset. Frailty factors had occurred in the majority of patients (87%) and the main sites were: ribs (75%), hip (62%), pelvis (25%), tibia (25%), and vertebral (12%). All patients had shown low serum phosphorus, reduced BMP and elevated ALP levels at diagnosis and they maintained these features on their first visit to our institution. All patients had high (n = 6) or inappropriately normal (n = 2) values of FGF23 (median FGF23: 80.8 pg/mL). All of them had low BMD. BMD and Z-score values are described in Table 2.

Fatigue, HRQoL, pain, and muscle assessment

The mean FACIT-Fatigue score in our cohort was 28.4 ± 9.6 (25 ± 3.5 in men and 31 ± 12.6 in women) (Table 3). These values were significantly lower in comparison with those of the US general population (p < .0001), which means patients with TIO show higher levels of fatigue. The questions that reflected higher level of fatigue (50% of the cohort answered “very much” or “quite a bit”) were: “I have to limit my social activity because I am tired” and “I have trouble starting things because I am tired.”

The physical SF-36 summary measure showed significant lower values in comparison with an Argentinian population with chronic conditions (mean: 20.4 versus 45.9, p < .0001) but the mental summary measure was not statistically different from this reference population (mean: 46.4 versus 49.9, p = 0.352). All physical domains of the SF-36 were statistically lower than in the general population. The domains with the lowest scores were: physical role functioning (which evaluates limitations in usual role activities due to physical health problems), followed by physical functioning and bodily pain (Table 3). Although the mental summary measure was not statistically different from the reference population, specific mental domains such as energy/fatigue and social functioning had lower scores than the general population (47 versus 62.6, p = 0.0183 and 40.2 versus 81.14, p < .0001, respectively). No differences with the general population were found regarding the domains of emotional well-being and role limitations due to emotional problems (Table 3).

According to the BPI-sf, patients had moderate average pain (mean 5 ± 2.4) and the pain interfered severely with walking (mean 9 ± 1), general activities (mean 8.5 ± 1.6), work (8.6 ± 4.2), and mood (7 ± 2.4) (Table 3). The most frequent sites

### Table 2. BMD of Patients in Our Cohort

| BMD | Value       |
|-----|-------------|
| Spine L1–L4 BMD (g/cm²), mean ± SD | 0.856 ± 0.19 |
| Spine L1–L4 Z-score, mean ± SD | −2.6 ± 1.3 |
| Left total hip BMD (g/cm²), mean ± SD | 0.712 ± 0.09 |
| Left total hip Z-score, mean ± SD | −2.8 ± 1.6 |

*BMD = bone mineral density; SD = standard deviation.

### Table 3. Fatigue, Pain, and Health-Related Quality of Life Assessment

| Assessment | Our cohort (n = 8) | General population³ | p      |
|------------|--------------------|----------------------|--------|
| FACIT-F    | 28.4 ± 9.6         | 43.6 ± 9.4           | <.0001b|
| SF-36      |                    |                      |        |
| Physical functioning | 18 ± 25 | 89.1 ± 14.4 | <.0001b|
| Physical role functioning | 0 | 83.7 ± 30.4 | <.0001b|
| Bodily pain | 27.8 ± 6 | 80.6 ± 22 | <.0001b|
| General health | 44 ± 9.6 | 71.5 ± 16.5 | <.0001b|
| Energy/fatigue | 47 ± 16 | 62.6 ± 19.8 | .0183b|
| Emotional well-being | 61.6 ± 8.3 | 67.3 ± 19 | .3964 |
| Role limitations due to emotional problems | 60 ± 43.5 | 78.9 ± 33.2 | .1083 |
| Social functioning | 40.2 ± 16.5 | 81.14 ± 22.5 | <.0001b|
| Physical summary measurements | 20.4 ± 8 | 45.9 ± 11.4 | <.0001b|
| Mental summary measurements | 46.4 ± 6 | 49.9 ± 10 | .352 |

**BPI-pain severity score**

- Average: 5 ± 2.4
- Worst: 6 ± 2
- Least: 3.6 ± 1.7
- Pain now: 3.8 ± 2.1

**BPI-interference score**

- General activity: 8.5 ± 1.6
- Walking: 9 ± 1
- Work: 8.6 ± 4.2
- Sleep: 5 ± 3.8
- Relations with others: 4.7 ± 4.3
- Enjoyment of life: 6.7 ± 3.2
- Mood: 7 ± 2.4

*Values are expressed in means ± SD.

BPI = Brief Pain Inventory; FACIT-F = Functional Assessment of Chronic Illness Therapy-Fatigue; SD = standard deviation; SF-36 = 36-item Short Form survey.

³For FACIT-F scores, US general population was used,(7) and for SF-36, Argentinean general population was considered.(8)

bStatistically significant values.
Muscle mass, Strength, and Physical Performance Assessment

|                          | Women (n = 5) | Men (n = 3) | Total (n = 8) |
|--------------------------|---------------|-------------|--------------|
| Muscle mass              |               |             |              |
| ASM index (kg/m²), mean ± SD | 5 ± 1.9   | 7.3 ± 0.1  | —            |
| Low muscle mass, n (%)   | 3 (60)        | 1 (34)      | 4 (50)       |
| Muscle strength          |               |             |              |
| Hand grip (kg), mean ± SD | 11 ± 10.3  | 31 ± 1.4    | —            |
| Low muscle strength, n (%)| 4 (80)      | 1 (34)      | 5 (62)       |
| Physical performance     |               |             |              |
| Low walking speed test, n (%)| 5 (100)  | 2 (67)      | 7 (87)       |
| Low sit-to-stand test, (%)| 4 (80)     | 3 (100)     | 7 (87)       |

ASM = appendicular skeletal muscle mass; SD = standard deviation.

Table 4.

Discussion

Our study describes the extremely high clinical burden of disease on eight adult patients with TIO referred to our institution. This cohort showed higher levels of fatigue than a reference population from the United States, lower values in the physical domains of the SF-36 than in an Argentinian population with chronic conditions and a severe interference of pain with walking, general activities, work, and mood. Regarding muscle assessment, in nearly all patients, at least one physical performance test was negatively affected.

Lower FACIT-Fatigue values significantly correlated with lower scores in the physical functioning domain of the SF-36 (p = 0.836, p = 0.038) and with higher interference of pain with general activity (p = −0.713, p = 0.047). No other significant correlation was found between age at diagnosis, time from onset to diagnosis, phosphate levels, FACIT-Fatigue score, SF-36 domains, BPI-sf values, and muscle parameters.

Fatigue is one of the main symptoms in patients with TIO and it is related to muscle weakness due to longstanding hypophosphatemia. Its assessment is complex because psychological and physiological factors may be involved. The FACIT-Fatigue scale has not been validated in our country. It is worth mentioning that Mallinson and colleagues reported that the FACIT-Fatigue scores in the range of 30 and below were related to an increased difficulty in performing everyday activities such as folding laundry or getting dressed. In line with these results, the subitem “fatigue/energy” in the SF-36 score in our patients was significantly affected in comparison with the Argentinian population with chronic conditions (47 versus 62.6, p = 0.0183) and the limitations in usual role activities because of physical health problems showed the worst measurement in this scale. Moreover, the FACIT-Fatigue values correlate positively with physical functioning domain in the SF-36 scale (p = 0.836, p = 0.038). The FACIT-Fatigue values in our cohort were similar to the mean score reported in cancer patients with the lowest performance status in the Eastern Cooperative Oncology Group Performance Status (grade 3 and 4, mean value 23.1). Grades 3 and 4 of this scale represent patients capable of only limited self-care, confined to bed or chair more than 50% of waking hours or completely disabled, respectively.

Our results clearly show that patients with TIO had poor HRQoL in comparison with the general population. Differences were particularly notable in the physical domains of the SF-36. Besides, the energy/fatigue and social functioning domains were also lower than in the general population. An impaired HRQoL was also found in patients with XLH (a genetic form of a FGF23-related hypophosphatemic disease). XLH patients showed mean values of SF-36 score similar to patients with chronic musculoskeletal diseases such as rheumatoid arthritis or juvenile idiopathic arthritis. Indeed, in our population, the physical summary measurements were significantly lower even in comparison with a population with chronic conditions in Argentina. Some mental domains (but not the mental summary measurements) were also negatively affected in our cohort. A similar pattern of HRQoL was found in patients with rheumatoid arthritis and osteogenesis imperfecta denoting the multifaceted impact of HRQoL on patients with chronic conditions.
Bone pain was reported in nearly 100% of patients with TIO. In fact, all patients in our study presented with bone pain as an initial symptom. Consistent with the FACT-Fatigue and the SF-36 scores, pain in patients with TIO had higher interference with physical activities including working and walking. Besides, a severe interference with mood and a moderate interference with enjoyment of life were also detected, which might suggest that the psychological and emotional impact of pain needs to be addressed when treating patients with TIO.

It has been shown that hypophosphatemia resulting from vitamin D deficiency is the cause of muscle weakness in patients with osteomalacia. It is not definitely clear why phosphate deficiency causes muscle weakness but it is most likely due to the metabolism of ATP, phosphorylation of myosin and actin filaments, alteration in ion pumps and calcium handling, or changes in mitochondrial function. Although chronic hypophosphatemia is a well-known factor of skeletal muscle weakness, muscle strength and physical performance have not been quantified in patients with hypophosphatemic disorders. In our study, nearly all patients showed low physical performance denoting a severe compromise in muscle quality.

This study has several limitations. First, the questionnaires we used are not targeted for this specific condition and the small sample size did not allow us to make extensive internal and external validations of the instruments used. Indeed, we could not find any significant correlation between clinical factors and the different scales used in our study, probably due to the low number of patients included. Second, although the study was not limited to patients without tumor localization or without remission, we did not have the chance to evaluate patients with clinical remission after surgery which might have given us a wider picture of the disease. We also did not have a control group to compare their measurements with those of our cohort. Third, the patients in our cohort were evaluated at a reference center and thus, they might have been more severely affected, showing a higher rate of complications than the overall population (referral bias).

To our best knowledge, this is the first study aimed to quantify fatigue, pain, HRQoL, and muscle health in a group of adult patients with non-cured TIO. According to our results, it seems that this disease has a severe negative impact on patients’ QoL, similar to that of advanced cancer. We hope our results contribute to a better understanding of the burden of disease on TIO patients and establish the basis for future studies—with larger samples—which will make it possible to assess the efficacy of therapeutic interventions.

**Disclosures**

MBZ has received honoraria from Ultragenyx for participation in an advisory board. HC is a member of the XLH DMP Steering Committee and received honoraria from Ultragenyx for participation in an advisory board. The rest of the authors declare no potential conflicts of interest of this work.

**Acknowledgments**

This study was partially funded by Ultragenyx as an Investigator Sponsored Trial and by Fundación Investigaciones Metabólicas (FIM). The funders of the study had no role in the study design, data collection, data interpretation, or writing of the report. The authors had full access to all the data and had final responsibility for the decision to submit for publication. We are sincerely grateful to Susana Carballo for proofreading the manuscript.

**Author Contributions**

**Fernando Jerkovich:** Formal analysis; writing-original draft.
**Selva Núñez:** Data curation. **Yamile Mocarbel:** Data curation. **Anaíla Pignatta:** Data curation. **Natalia Elías:** Data curation. **Hamilton Cassinelli:** Data curation. **Adriana Díaz:** Data curation. **Carlos Vigovich:** Data curation. **María Balonga:** Data curation. **Ana Cohen:** Data curation. **Giselle Mumbach:** Data curation. **Sofía González:** Data curation. **Jose Zanchetta:** Data curation. **Maria Zanchetta:** Conceptualization; data curation; formal analysis; supervision; writing-review and editing.

**Authors’ roles**

MBZ collected and analyzed the data, designed the study and revised the manuscript. FJ analyzed and interpreted the data and drafted the manuscript. SN, VM, AP, NE, HC, AD, CAV, CB, CC, GM, SG, and JRZ collected the data. MBZ and FJ are responsible for the integrity of the data analysis. All authors read and approved the final manuscript.

**Peer Review**

The peer review history for this article is available at https://publons.com/publon/10.1002/jbm4.10436.

**References**

1. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86(2):497–500.
2. Boland JM, Tebben PJ, Folpe AL. Phosphaturic mesenchymal tumors: what an endocrinologist should know. J Endocrinol Invest. 2018;41(10):1173–84.
3. Li X, Jiang Y, Luo L, et al. Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res. 2020;35(10):1173–84.
4. Li X, Jiang Y, Wang Q, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017;64(7):675–83.
5. Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017;7:90–7.
6. Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008;42(6):1235–9.
7. Yellen SB, Della CF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT)–general symptom measurement system. J Pain Symptom Manage. 1997;13(2):63–74.
8. Hahn EA, Rao D, Della C, Choi SW. Comparability of interview- and self-administration of the Functional Assessment of Cancer Therapy–General (FACT-G) in English- and Spanish-speaking ambulatory cancer patients. Med Care. 2008;46(4):423–31.
9. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–38.
10. Augustovski F, Lewin G, García Elorrio E, Rubinstein A. The Argentine-Spanish SF-36 Health Survey was successfully validated for local outcome research. J Clin Epidemiol. 2008;61(12):1279–84.
11. Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res. 2001;10(5):395–404.

12. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–38.

13. Badia X, Muriel C, Gracia A, et al. Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain. Med Clin (Barr). 2003;120(2):52–9. Spanish.

14. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277–84.

15. Theodore-Oklota C, Bonner N, Spencer H, Arbuckle R, Chen CY, Skrinar A. Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC® as clinical trial end points. Value Health. 2018;21(8):973–83.

16. Gould H, Brennan SL, Kotowicz MA, Nicholson GC, Pasco JA. Total and appendicular lean mass reference ranges for Australian men and women: the Geelong osteoporosis study. Calcif Tissue Int. 2014;94(4):363–72.

17. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.

18. González G, Baudrand R, Sepúlveda MF, et al. Tumor-induced osteomalacia: experience from a South American academic center. Osteoporos Int. 2017;28(7):2187–93.

19. Jerkovich F, Moncet D, Babini S, Zoppi JA, Graciolli F, Oliveri B. Osteomalacia oncogénica. Presentación de dos casos (oncogenic osteomalacia. Report of two cases). Medicina (B Aires). 2015;75(1):37–40.

20. Sánchez A, Castiglioni A, Cóccaro N, et al. Osteomalacia por tumor secreter de FGF-23 (osteomalacia due to a tumor secreting FGF-23). Medicina (B Aires). 2013;73(1):43–6.

21. Mallinson T, Cella D, Cashy J, Holzner B. Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage. 2006;31(3):229–41.

22. Oken MM, Creech RH, Torney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

23. Forestier-Zhang L, Watts L, Turner A, et al. Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphataemia and fibrous dysplasia. Orphanet J Rare Dis. 2016;11(1):160.

24. Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ. Exploring the burden of X-linked hypophosphataemia: a European multi-country qualitative study. Qual Life Res. 2020;29:1883–93.

25. Che H, Roux C, Etchet A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):323–33.

26. Rosa-Gonçalves D, Bernardes M, Costa L. Quality of life and functional capacity in patients with rheumatoid arthritis—cross-sectional study. Reumatol Clin. 2018;14(6):360–6.

27. Hald JD, Folkestad L, Harsløf T, Brixen K, Langdahl B. Health-related quality of life in adults with osteogenesis imperfecta. Calcif Tissue Int. 2017;101(5):473–8.

28. Schubert L, DeLuca HF. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch Biochem Biophys. 2010;500(2):157–61.

29. Wacker MJ, Touchberry CD, Silswal N, et al. Skeletal muscle, but not cardiovascular function, is altered in a mouse model of autosomal recessive hypophosphatemic rickets. Front Physiol. 2016;7:173.